← All trials
NCT05040464
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2021
- Primary completion
- Aug 31, 2023
- Completion date
- Mar 31, 2024
- First posted
- Sep 10, 2021
- Last posted
- Sep 10, 2021
- Enrollment
- 166
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Picardie Jules VerneLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.